210 related articles for article (PubMed ID: 38170429)
1. Updated Response Assessment in Neuro-Oncology (RANO) for Gliomas.
Youssef G; Wen PY
Curr Neurol Neurosci Rep; 2024 Feb; 24(2):17-25. PubMed ID: 38170429
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma.
Youssef G; Rahman R; Bay C; Wang W; Lim-Fat MJ; Arnaout O; Bi WL; Cagney DN; Chang YS; Cloughesy TF; DeSalvo M; Ellingson BM; Flood TF; Gerstner ER; Gonzalez Castro LN; Guenette JP; Kim AE; Lee EQ; McFaline-Figueroa JR; Potter CA; Reardon DA; Huang RY; Wen PY
J Clin Oncol; 2023 Jun; 41(17):3160-3171. PubMed ID: 37027809
[TBL] [Abstract][Full Text] [Related]
3. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.
Wen PY; van den Bent M; Youssef G; Cloughesy TF; Ellingson BM; Weller M; Galanis E; Barboriak DP; de Groot J; Gilbert MR; Huang R; Lassman AB; Mehta M; Molinaro AM; Preusser M; Rahman R; Shankar LK; Stupp R; Villanueva-Meyer JE; Wick W; Macdonald DR; Reardon DA; Vogelbaum MA; Chang SM
J Clin Oncol; 2023 Nov; 41(33):5187-5199. PubMed ID: 37774317
[TBL] [Abstract][Full Text] [Related]
4. Response Assessment in Neuro-Oncology Criteria and Clinical Endpoints.
Huang RY; Wen PY
Magn Reson Imaging Clin N Am; 2016 Nov; 24(4):705-718. PubMed ID: 27742111
[TBL] [Abstract][Full Text] [Related]
5. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group.
Vogelbaum MA; Jost S; Aghi MK; Heimberger AB; Sampson JH; Wen PY; Macdonald DR; Van den Bent MJ; Chang SM
Neurosurgery; 2012 Jan; 70(1):234-43; discussion 243-4. PubMed ID: 21593697
[TBL] [Abstract][Full Text] [Related]
6. Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas.
Jaspan T; Morgan PS; Warmuth-Metz M; Sanchez Aliaga E; Warren D; Calmon R; Grill J; Hargrave D; Garcia J; Zahlmann G
AJNR Am J Neuroradiol; 2016 Sep; 37(9):1581-7. PubMed ID: 27127006
[TBL] [Abstract][Full Text] [Related]
7. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
[TBL] [Abstract][Full Text] [Related]
8. Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study.
Kickingereder P; Isensee F; Tursunova I; Petersen J; Neuberger U; Bonekamp D; Brugnara G; Schell M; Kessler T; Foltyn M; Harting I; Sahm F; Prager M; Nowosielski M; Wick A; Nolden M; Radbruch A; Debus J; Schlemmer HP; Heiland S; Platten M; von Deimling A; van den Bent MJ; Gorlia T; Wick W; Bendszus M; Maier-Hein KH
Lancet Oncol; 2019 May; 20(5):728-740. PubMed ID: 30952559
[TBL] [Abstract][Full Text] [Related]
9. Updated response assessment criteria for high-grade glioma: beyond the MacDonald criteria.
Sharma M; Juthani RG; Vogelbaum MA
Chin Clin Oncol; 2017 Aug; 6(4):37. PubMed ID: 28841799
[TBL] [Abstract][Full Text] [Related]
10. Pros and cons of current brain tumor imaging.
Ellingson BM; Wen PY; van den Bent MJ; Cloughesy TF
Neuro Oncol; 2014 Oct; 16 Suppl 7(Suppl 7):vii2-11. PubMed ID: 25313235
[TBL] [Abstract][Full Text] [Related]
11. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
Moon HH; Kim HS; Park JE; Kim YH; Kim JH
BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252
[TBL] [Abstract][Full Text] [Related]
12. Artificial intelligence (AI)-based decision support improves reproducibility of tumor response assessment in neuro-oncology: An international multi-reader study.
Vollmuth P; Foltyn M; Huang RY; Galldiks N; Petersen J; Isensee F; van den Bent MJ; Barkhof F; Park JE; Park YW; Ahn SS; Brugnara G; Meredig H; Jain R; Smits M; Pope WB; Maier-Hein K; Weller M; Wen PY; Wick W; Bendszus M
Neuro Oncol; 2023 Mar; 25(3):533-543. PubMed ID: 35917833
[TBL] [Abstract][Full Text] [Related]
13. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
[TBL] [Abstract][Full Text] [Related]
14. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials.
Ellingson BM; Wen PY; Cloughesy TF
Neurotherapeutics; 2017 Apr; 14(2):307-320. PubMed ID: 28108885
[TBL] [Abstract][Full Text] [Related]
15. Classification of High-Grade Glioma into Tumor and Nontumor Components Using Support Vector Machine.
Blumenthal DT; Artzi M; Liberman G; Bokstein F; Aizenstein O; Ben Bashat D
AJNR Am J Neuroradiol; 2017 May; 38(5):908-914. PubMed ID: 28385884
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
Gahrmann R; van den Bent M; van der Holt B; Vernhout RM; Taal W; Vos M; de Groot JC; Beerepoot LV; Buter J; Flach ZH; Hanse M; Jasperse B; Smits M
Neuro Oncol; 2017 Jun; 19(6):853-861. PubMed ID: 28204639
[TBL] [Abstract][Full Text] [Related]
17. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
Wen PY; Macdonald DR; Reardon DA; Cloughesy TF; Sorensen AG; Galanis E; Degroot J; Wick W; Gilbert MR; Lassman AB; Tsien C; Mikkelsen T; Wong ET; Chamberlain MC; Stupp R; Lamborn KR; Vogelbaum MA; van den Bent MJ; Chang SM
J Clin Oncol; 2010 Apr; 28(11):1963-72. PubMed ID: 20231676
[TBL] [Abstract][Full Text] [Related]
18. Response assessment in neuro-oncology.
Quant EC; Wen PY
Curr Oncol Rep; 2011 Feb; 13(1):50-6. PubMed ID: 21086192
[TBL] [Abstract][Full Text] [Related]
19. Earliest radiological progression in glioblastoma by multidisciplinary consensus review.
Eijgelaar RS; Bruynzeel AME; Lagerwaard FJ; Müller DMJ; Teunissen FR; Barkhof F; van Herk M; De Witt Hamer PC; Witte MG
J Neurooncol; 2018 Sep; 139(3):591-598. PubMed ID: 29777418
[TBL] [Abstract][Full Text] [Related]
20. Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus.
Schiff D; Van den Bent M; Vogelbaum MA; Wick W; Miller CR; Taphoorn M; Pope W; Brown PD; Platten M; Jalali R; Armstrong T; Wen PY
Neuro Oncol; 2019 Jul; 21(7):837-853. PubMed ID: 30753579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
